microdosing glp-1 perimenopause Let’s talk about medications in the context of and menopause, because this is where the conversation most often gets flattened into something it is not. This is not about vanity, GLP-1 Agonists in Perimenopause: Unique

Unlike corticosteroids or broad immunosuppressants, KPV does not appear to suppress immune function globally its NF-kB inhibition is targeted and does not eliminate the immune response, only attenuates the pro-inflammatory cascade

Its used to address primary and secondary carnitine deficiency, and is also associated with supporting angina management, alongside broader use in wellness and metabolic support

GLP-1 receptor agonists cause fatigue primarily through indirect mechanisms including substantial caloric restriction from appetite suppression, gastrointestinal side effects leading to dehydration and nutritional deficits, and metabolic adaptation during weight loss

These formulations can provide synergistic benefits, addressing multiple skin concerns simultaneously